Actively Recruiting
Amino Acid Effluent Loss During Continuous Renal Replacement Therapy: An Explorative Non-interventional Pilot Study
Led by Medical University of Vienna · Updated on 2025-05-25
30
Participants Needed
1
Research Sites
13 weeks
Total Duration
On this page
Sponsors
M
Medical University of Vienna
Lead Sponsor
K
Karolinska Institutet
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying amino acid loss during continuous renal replacement therapy (CRRT) in intensive care patients to understand how much amino acid is lost over time and how plasma amino acid levels change with and without CRRT. This observational study aims to measure these changes to improve knowledge about nutritional and metabolic effects in such patients. The study includes two groups: 20 intensive care patients undergoing CRRT and 10 intensive care patients not receiving renal replacement therapy. Amino acid concentrations will be measured in the blood, effluent, and urine over the entire treatment period using advanced measurement techniques. Secondary outcomes include monitoring nitrogen balance, blood urea nitrogen, creatinine, albumin, and nutritional and mobility assessments such as indirect calorimetry and muscle strength scoring. Participants will be monitored throughout their ICU stay, with amino acid levels and other metabolic markers measured regularly for up to 30 days. The duration of CRRT, length of ICU and hospital stay, and mortality will also be tracked up to one year. This non-interventional pilot study collects data during routine care without altering treatment, focusing on detailed biochemical and functional evaluations.
CONDITIONS
Brief Title
Amino Acid Loss During Continuous Renal Replacement Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Postoperative ICU patients
- Age 18 years or older
- Patients receiving enteral and/or parenteral nutrition according to internal standards
- For CRRT group: planned continuous renal replacement therapy of any type
- For non-CRRT group: no current or recent (within 30 days) renal replacement therapy
- For non-CRRT group: no chronic kidney disease stage G3-G5
You will not qualify if you...
- Preoperative intensive care patients
- Patients with liver cirrhosis stage 1-3 by Child-Pugh classification
- Patients with acute liver failure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 30 days
Participants are observed during their stay in intensive care with or without continuous renal replacement therapy. Measurements of amino acid concentrations and other nutritional and mobility assessments are collected over the course of treatment.
Multiple visits depending on ICU stay and treatment duration
Duration - Up to 1 year
Participants are monitored for length of ICU and hospital stay, including mortality outcomes, to assess longer term effects after treatment.
Periodic assessments during hospital stay and follow-up
Trial Site Locations
Total: 1 location
1
Medical University of Vienna
Vienna, State of Vienna, Austria, 1090
Actively Recruiting
Research Team
S
Sarah Yadavalli, Dr.
A
Arabella Fischer, Dr.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2